Huadong Medicine

elsewhere's corpus doesn't carry a full profile of Huadong Medicine — it surfaces only as a partner in AI-driven drug discovery, via two Qiming Venture Partners weeklies. In one, Huadong Medicine adopted DeepWise's Uni-FEP free-energy perturbation tool for drug R&D ; in the other, it worked with Qiming portfolio company Insilico Medicine, using generative AI and physics-based molecular modeling to discover a novel small-molecule inhibitor targeting the WDR5–MYC protein-protein interaction , both reported in mid-2025. Anything beyond that — its founding, scale, or business lines — isn't covered here.